Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus MIRALUMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus MIRALUMA.
MACROTEC vs MIRALUMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
MIRALUMA (garadacimab) is a monoclonal antibody that binds to activated factor XII (FXIIa) and inhibits its activity, thereby blocking the contact activation pathway of the coagulation cascade. This prevents the generation of bradykinin, reducing vascular permeability and swelling in hereditary angioedema (HAE).
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
MIRALUMA (mirvetuximab soravtansine) is administered intravenously at 6 mg/kg adjusted ideal body weight (AIBW) once every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
20 hours; prolonged to 30-40 hours in renal impairment requiring dose adjustment
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
90% renal as unchanged drug; 10% biliary/fecal
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical